<DOC>
	<DOCNO>NCT02420717</DOCNO>
	<brief_summary>The goal clinical research study learn ruxolitinib dasatinib combination chemotherapy help control Ph-like ALL . The safety drug combination also study .</brief_summary>
	<brief_title>Ruxolitinib Dasatinib With Chemotherapy Patients With Philadelphia Chromosome ( Ph ) -Like Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign 1 2 study group , base molecular type disease . You study staff know study drug receive : - Participants Group A receive ruxolitinib . - Participants Group B receive dasatinib . Study Drug Administration : Each study cycle 21 day . Participants Group A take ruxolitinib tablet mouth 2 time day ( 12 hour apart ) , without food . Participants Group B take dasatinib tablet mouth 1 time day , without food . You take study drug time day . If doctor think need , may receive steroid and/or hydroxyurea white blood cell count high . If disease respond treatment either ruxolitinib dasatinib alone , continue receive drug . That first cycle therapy call Cycle 0 . Your next cycle dasatinib ruxolitinib alone continue call Cycle 0 . Once move intensive chemotherapy ( describe ) , first cycle call Cycle 1 . If disease respond treatment end first cycle ruxolitinib dasatinib , also receive 2Â½ year chemotherapy treatment . You receive 8 cycle intensive chemotherapy , use 2 different chemotherapy schedule . Once complete intensive chemotherapy , receive 2 year maintenance chemotherapy . During intensive chemotherapy maintenance chemotherapy , may continue take ruxolitinib dasatinib every day , long receive benefit intolerable side effect . Chemotherapy give several different way : - By mouth - By vein , central venous catheter ( CVC ) : A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . - Intrathecal administration , lumbar puncture ( spinal tap ) : A spinal tap ( also call lumbar puncture ) fluid surround spinal cord remove insert needle low back . The affected area numb local anesthetic procedure . It also use give chemotherapy . The number dose receive depend many dos study doctor think need . Occasionally , sample fluid obtain spinal tap may test leukemia . Your chemotherapy dos may raise lower , depend side effect . You receive drug chemotherapy help prevent low risk certain side effect , include tumor lysis syndrome ( breakdown product cancer cell enter blood stream , may cause possible weakness , low blood pressure , muscle cramp , kidney damage , and/or organ damage ) . Intensive Chemotherapy : You receive several drug ( list ) part chemotherapy . Each cycle intensive chemotherapy 21 day . You may receive 8 cycle intensive chemotherapy hospital . You need stay hospital first 4-5 day cycle . Hyper-CVAD : Cycles 1 , 3 , 5 , 7 : - On Days 1-3 cycle , receive cyclophosphamide vein 3 hour , 2 time day ( every 12 hour ) . - On Days 1-3 cycle , start 1 hour cyclophosphamide infusion , receive MESNA vein 16 hour . MESNA give low risk side effect . - On Day 4 cycle , receive doxorubicin vein 24-48 hour . On Days 4 11 ( +/- 2 day ) cycle , receive vincristine vein 30 minute . - On Days 1-4 11-14 ( +/- 2 day ) cycle , take dexamethasone mouth 1 time day vein 30 minute . - If doctor think need , Days 1 11 Cycles 1 3 , may also receive rituximab vein several hour . Methotrexate alternate cytarabine vein : Cycles 2 , 4 , 6 , 8 : - On Day 1 cycle , receive methotrexate vein 24 hour ( +/- 3 hour ) . - On Days 2-5 cycle , receive leucovorin vein mouth every 6 hour , begin 12 hour ( +/- 2 hour ) finish receive methotrexate . Each infusion last 1 hour . Leucovorin give low risk side effect mouth sore kidney damage . - On Days 1-3 cycle , receive Solu-Medrol ( methylprednisolone ) vein every 12 hour . Each infusion last 2 hour . - On Days 2 3 cycle , receive cytarabine vein every 12 hour . Each infusion last 2 hour . - If doctor think need , Days 1 8 Cycles 2 4 , may also receive rituximab vein several hour . Additional Treatment Intensive Chemotherapy : - If doctor think need , Day 2 Cycles 1 , 2 , 3 , 4 ( +/- 2 day ) , receive intrathecal methotrexate help low risk disease come back fluid surround brain . - If doctor think need , Day 7 Cycles 1 , 2 , 3 , 4 ( +/- 2 day ) , receive intrathecal cytarabine help low risk disease come back fluid surround brain . - You also receive either filgrastim every day pegfilgrastim cycle . The drug give injection skin , white blood cell count recover . Your study doctor tell happen . As long disease respond therapy intolerable side effect , continue intensive chemotherapy 8 course . At point , go maintenance therapy phase . Maintenance Chemotherapy : Each maintenance cycle 28 day . Maintenance chemotherapy last 2 year complete 8 course intensive chemotherapy . During maintenance chemotherapy : - You take mercaptopurine tablet mouth 3 time day . - You take methotrexate tablet mouth week . - On Day 1 cycle , receive vincristine vein 30 minute . - On Days 1-5 cycle , take prednisone mouth . Study Visits : On Day 1 Cycle 0 : - You physical exam . - Blood ( 1 tablespoon ) drawn routine test . - For Day 1 test , test procedure last 3 day , may need repeat . On Days 8 15 Cycle 0 , physical exam . Every week Cycle 0 , blood ( 1 tablespoon time ) drawn routine test 3 time week . On Day 21 every cycle , bone marrow aspiration and/or biopsy , check status disease . Once doctor believe disease show enough response , do every 2-3 cycle point . On Day 1 Cycle 0 every cycle , physical exam . During Intensive Chemotherapy cycle , blood ( 1 tablespoon time ) drawn routine test every week . During Maintenance Chemotherapy cycle , routine blood sample draw 1 time every month . On Day 1 every even-numbered cycle ( Cycles 2 , 4 , 6 , ) , x-ray chest Length Treatment : You may receive intensive chemotherapy 8 cycle ( 8 month ) maintenance therapy 2 year . You may continue take ruxolitinib dasatinib every day long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow-up : You follow-up visit 30 day last dose study drug . At visit , ask side effect may . If make clinic visit , do phone member study staff . The phone call last 10 minute . This investigational study . Ruxolitinib FDA approve commercially available treatment myelofibrosis . Its use study investigational . The study doctor explain ruxolitinib design work . Dasatinib FDA approve commercially available treatment CML Philadelphia chromosome-positive ALL . All drug use study FDA approve commercially available . Their use together study investigational . The study doctor explain study drug ( ) design work . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Up 92 participant take part study . All enrol MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Patients previously treat Bcell ALL ( relapse and/or refractory prior therapy ) 2 . Bone marrow involvement &gt; /= 5 % lymphoblasts 3 . Age &gt; /= 10 year 4 . Documented genetic lesion ( ) know confer susceptibility inhibition either ruxolitinib dasatinib CRLF2 positivity flow cytometry ( Ruxolitinib cohort ) 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 6 . Adequate organ function ( total bilirubin &lt; 2.0 mg/dL , SGPT SGOT &lt; 3 x upper limit normal [ ULN ] , creatinine &lt; 2 mg/dL ) 7 . Females childbearing potential must negative serum urine beta human chorionic gonadotropin ( BetahCG ) pregnancy test result within 14 day prior first dose study drug must agree use effective contraception method study 30 day follow last dose study drug . Females non childbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . Appropriate method birth control include follow : Any 2 follow method use together : Birth control implant , injection , pill ( except progesterone pill ) , Intrauterine device ( IUD ) , Vasectomy , Tubal Ligation , Barrier method ( female male condom spermicide , cervical cap spermicide , diaphragm spermicide ) ; Male condom spermicide diaphragm ; Male condom spermicide cervical cap 8 . ( Continuation # 7 ) Unacceptable method birth control include use birth control , withdrawal , rhythm method , vaginal sponge , barrier method use spermicide , progesterone pill , use male female condom time . 9 . Males partner childbearing potential must agree use effective contraceptive method study 30 day follow last dose study drug 10 . Patients legally authorize representative must provide write informed consent 1 . Burkitt 's Leukemia Lymphoma , Tcell ALL lymphoblastic lymphoma 2 . Patients undergone prior allogeneic stem cell transplant within 3 month active graft versus host disease 3 . Patient pregnant breastfeeding 4 . Patients uncontrolled active infection ( Fever &gt; /= 38 degree C , Septic shock ) 5 . Isolated extramedullary relapse ( i.e . testicular , central nervous system ) 6 . Current chronic hepatitis B C infection , know seropositivity HIV 7 . Concurrent chemotherapy ( except intrathecal chemotherapy ) 8 . Major surgery within 4 week prior first study dose 9 . Systemic chemotherapy/radiotherapy/investigational therapy within 14 day ( exception hydroxyurea steroid ) prior start therapy . For patient receive ALL maintenance 6mercaptopurine , methotrexate , vincristine , steroids agent discontinue least 48 hour prior start study drug . For patient oral targeted therapy ( imatinib , dasatinib , ponatinib ) , agent discontinue least 48 hour prior start study drug . 10 . Patients must recover acute non hematologic toxicity ( &lt; /= grade 1 ) previous therapy prior enrollment 11 . Known active central nervous system ( CNS ) leukemia , define unequivocal morphologic evidence lymphoblast cerebrospinal fluid ( CSF ) , use CNSdirected local treatment active disease within prior 28 day , symptomatic CNS leukemia ( i.e. , cranial nerve palsy significant neurologic dysfunction ) within 28 day . Patients may history CNS leukemic involvement definitively treat prior therapy evidence active disease ( define &gt; /= 2 consecutive spinal fluid assessment evidence disease ) time registration . Prophylactic intrathecal chemotherapy criterion exclusion . 12 . Patients active heart disease ( NYHA class 34 assessed history physical examination , unstable angina/stroke/myocardial infarction within last 6 month ) 13 . Patients cardiac ejection fraction ( measure either Multigated Acquisition ( MUGA ) scan echocardiogram ) &lt; 40 % . ( Note : Patients prior anthracycline exposure &gt; 250 mg/m2 may eligible discussion PI ) . 14 . Second malignancy basal cell squamous cell carcinoma skin situ carcinoma cervix breast , unless successfully treat curative intent 2 year enter study 15 . Malabsorption syndrome condition preclude enteral route administration 16 . Patients require strong CYP3A4 inhibitor . ( Complete list inhibitor find : http : //medicine.iupui.edu/clinpharm/ddis/table.aspx ) 17 . Other severe acute chronic medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product administration may interfere interpretation study result and/or would make patient inappropriate enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Philadelphia Chromosome ( Ph ) -Like</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>Mercaptopurine</keyword>
	<keyword>6-MP</keyword>
	<keyword>Purinethol</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Jakafi</keyword>
	<keyword>INCB018424</keyword>
	<keyword>INC424</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine</keyword>
	<keyword>Arabinosine Hydrochloride</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubucin hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Solumedrol</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Depo-medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Solu-medrol</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Wellcovorin</keyword>
</DOC>